Predicting the Course of Graves ’ Orbitopathy Using Serially Measured TSH-Receptor Autoantibodies by Automated Binding Immunoassays and the Functional Bioassay
Horm Metab Res 2021; 53: 435-443 DOI: 10.1055/a-1525-2070The aim of the study was to investigate the use of serial measurements of
TSH-receptor autoantibodies (TRAb) with the newest available assay technology to
predict the course of Graves’ Orbitopathy (GO) during the first 24
months from disease onset. Serial serum samples from patients with GO (103
mild/135 severe) were collected between 2007 and 2017 and
retrospectively analyzed. The course of GO were classified into
mild/severe 12 months after manifestation (severe: NOSPECS≥5;
mild<5). TRAb were measured with automated binding immunoassays
(IU/l): TRAb Elecsys (Cobas, Roche), TRAb bridge assay (IMMULITE,
Siemens), and a cell-based bioassay (percent of specimen to reference ratio -
SRR%) (Thyretain, Quidel). Variable cut off levels of measured TRAb were
calculated at specificity of 90% from receiver operator curve (ROC)
analysis for several timepoints during the course of GO. To select one:
5–8 months after first GO symptoms, which is the timepoint for usual
referals for treatment mild course could be predicted at cut offs of 1.5
IU/l (Elecsys), 0.8 IU/l (Immulite) and 402% SRR
(Thyretain) and the risc of severe course has to be anticipated if TRAb are
above 11.6 IU/l (Elecsys), 6.5 IU/l (Thyretain), and
714% SRR (Thyretain). The Thyret...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: St öhr, Mareile Oeverhaus, Michael Lytton, Simon D. Horstmann, Mareike Zwanziger, Denise M öller, Lars Stark, Achim F ührer-Sakel, Dagmar Bechrakis, Nikolaos Berchner-Pfannschmidt, Utta Banga, J. Paul Philipp, Svenja Eckstein, Anja Tags: Endocrine Care Source Type: research